ADC Therapeutics (NYSE: ADCT) shares new updated corporate presentation

Rhea-AI Filing Summary

ADC Therapeutics SA released an updated corporate presentation and furnished it as an exhibit to a current report. The presentation is attached as Exhibit 99.1 and is meant to provide investors and other stakeholders with more detail about the company and its activities. The company notes that this material is being furnished under Regulation FD, which is designed to ensure fair disclosure of information. The presentation and related information are not treated as formally filed financial statements and are not automatically incorporated into other securities law filings unless specifically referenced.

false 0001771910 0001771910 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 12, 2026

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland (State or Other Jurisdiction of Incorporation) 001-39071  (Commission File Number) N/A (IRS Employer Identification Number) 

Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code) +41 21 653 02 00  (Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share	ADCT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 12, 2026, ADC Therapeutics SA (the “Company”) made available an updated corporate presentation, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information contained in this Item and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Corporate Presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADC Therapeutics SA
Date: January 12, 2026
	By:	/s/ Peter J. Graham
	Name:	Peter J. Graham
	Title:	Chief Legal Officer

FAQ

What did ADC Therapeutics SA (ADCT) disclose in this 8-K filing?

ADC Therapeutics SA furnished an updated corporate presentation as Exhibit 99.1 to a current report, providing additional information about the company under Regulation FD.

What is included as Exhibit 99.1 in ADC Therapeutics SA's 8-K?

Exhibit 99.1 contains an updated corporate presentation made available by ADC Therapeutics SA on January 12, 2026.

Is the ADC Therapeutics SA corporate presentation considered filed financial information?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to the liabilities of Section 18 of the Exchange Act.

Can the ADC Therapeutics SA presentation be incorporated into other SEC filings?

The presentation will only be incorporated into other Securities Act or Exchange Act filings if those filings specifically reference it.

Who signed the ADC Therapeutics SA 8-K related to the corporate presentation?

The report was signed on behalf of ADC Therapeutics SA by Peter J. Graham, the company's Chief Legal Officer.

On what date did ADC Therapeutics SA make the updated presentation available?

ADC Therapeutics SA made the updated corporate presentation available on January 12, 2026.